Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
21/07/2025 12:02
July 21 (Reuters) - Compugen Ltd CGEN.TA: COMPUGEN ANNOUNCES FIRST PATIENT DOSED IN COM701 GLOBAL PLATFORM TRIAL IN PLATINUM SENSITIVE OVARIAN CANCER COMPUGEN LTD - INTERIM ANALYSIS OF COM701 TRIAL PLANNED FOR 2026 Source text: ID:nPn2M6ngBa Further company coverage: CGEN.TA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025